Humira and Neurotoxicity - a phase IV clinical study of FDA data

Summary:

Neurotoxicity is reported as a side effect among people who take Humira (adalimumab), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Methotrexate, and have Inflammatory bowel disease.

The phase IV clinical study analyzes which people have Neurotoxicity when taking Humira. It is created by eHealthMe based on reports of 758,421 people who have side effects when taking Humira from the FDA, and is updated regularly.

What is Humira?

Humira has active ingredients of adalimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 761,396 Humira users. Check the latest studies of Humira.

What is Neurotoxicity?

Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system) is found to be associated with 676 drugs and 852 conditions by eHealthMe. Check the latest studies of Neurotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

758,421 people reported to have side effects when taking Humira.
Among them, 14 people (0.0%) have Neurotoxicity.

Among these 14 people:

How long have people been on Humira when they have Neurotoxicity? *

What is the gender of people who have Neurotoxicity when taking Humira? *

female: 64.29 %
male: 35.71 %

What is the age of people who have Neurotoxicity when taking Humira? *

What are other drugs people take besides Humira? *

What are other side effects people have besides Neurotoxicity? *

Joint Pain: 5 people, 35.71%
Drug Ineffective: 5 people, 35.71%
Headache (pain in head): 4 people, 28.57%
Dizziness: 3 people, 21.43%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 3 people, 21.43%
Weight Decreased: 2 people, 14.29%
Fever: 2 people, 14.29%
Loss Of Consciousness: 2 people, 14.29%
Joint Swelling: 2 people, 14.29%
Intestinal Polyp (small growths in the bowel with the potential for further growth): 2 people, 14.29%

What are the existing conditions these people have? *

Inflammatory Bowel Disease: 4 people, 28.57%
Iridocyclitis (inflammation of the iris and ciliary body of the eye): 2 people, 14.29%
Diarrhea: 2 people, 14.29%
Anal Fistula: 2 people, 14.29%
Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 1 person, 7.14%
Pain In Extremity: 1 person, 7.14%
Herpes Zoster: 1 person, 7.14%
Hepatitis C: 1 person, 7.14%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 7.14%
Angioedema (rapid swelling of the dermis): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Humira and have Neurotoxicity?

- Check whether Neurotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Humira:

Humira (761,396 reports)

Neurotoxicity treatments and more:

Neurotoxicity (16,742 reports)

Browse all side effects of Humira:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neurotoxicity:

Neurotoxicity (676 drugs)

Browse all the conditions that are associated with Neurotoxicity:

Neurotoxicity (852 conditions)

Related publications that referenced our studies

Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on adalimumab (the active ingredients of Humira) and Humira (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.